The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 0.00 (0.00%)
Spread: 1.50 (0.662%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 227.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

27 Dec 2023 07:00

RNS Number : 8395X
PureTech Health PLC
27 December 2023
 

27 December 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

22 December 2023

Number of ordinary shares purchased:

35,715

Highest price paid per share:

158.60p

Lowest price paid per share:

150.80p

Volume weighted average price paid per share:

152.90p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,614,428 ordinary shares in treasury and has 271,853,731 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 271,853,731 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

22/12/2023

08:13:02

279

151.8

CHIX

00383501662TRLO0.1.1

22/12/2023

08:13:02

32

152

CHIX

00383501663TRLO0.1.1

22/12/2023

08:15:39

279

151.8

CHIX

00383501962TRLO0.1.1

22/12/2023

08:15:39

20

152

CHIX

00383501963TRLO0.1.1

22/12/2023

08:17:59

279

151.8

CHIX

00383502239TRLO0.1.1

22/12/2023

08:18:01

208

151.8

BATE

00383502244TRLO0.1.1

22/12/2023

08:42:06

1016

152

XLON

00383505327TRLO0.1.1

22/12/2023

08:42:06

700

152

XLON

00383505328TRLO0.1.1

22/12/2023

08:42:06

66

152

XLON

00383505329TRLO0.1.1

22/12/2023

08:42:09

41

151.4

XLON

00383505336TRLO0.1.1

22/12/2023

08:42:12

25

151.4

XLON

00383505340TRLO0.1.1

22/12/2023

08:42:12

2194

151.4

XLON

00383505341TRLO0.1.1

22/12/2023

08:42:14

279

152

AQXE

00383505343TRLO0.1.1

22/12/2023

08:49:01

29

152

AQXE

00383506262TRLO0.1.1

22/12/2023

08:49:54

279

152

AQXE

00383506365TRLO0.1.1

22/12/2023

08:55:41

372

151.4

AQXE

00383507218TRLO0.1.1

22/12/2023

08:55:41

96

151.2

BATE

00383507219TRLO0.1.1

22/12/2023

08:55:41

893

151.4

CHIX

00383507220TRLO0.1.1

22/12/2023

08:55:41

144

151.2

BATE

00383507221TRLO0.1.1

22/12/2023

08:55:41

217

151.2

BATE

00383507222TRLO0.1.1

22/12/2023

08:55:41

412

151.2

BATE

00383507223TRLO0.1.1

22/12/2023

08:55:41

261

151.2

BATE

00383507224TRLO0.1.1

22/12/2023

08:55:41

237

151.4

CHIX

00383507225TRLO0.1.1

22/12/2023

08:55:41

1813

151

XLON

00383507226TRLO0.1.1

22/12/2023

08:55:41

52

151.4

TRQX

00383507227TRLO0.1.1

22/12/2023

08:55:41

447

151

XLON

00383507229TRLO0.1.1

22/12/2023

08:55:41

142

151.4

TRQX

00383507228TRLO0.1.1

22/12/2023

08:55:41

142

151.4

TRQX

00383507230TRLO0.1.1

22/12/2023

08:55:41

52

151.4

TRQX

00383507231TRLO0.1.1

22/12/2023

08:55:47

279

151

CHIX

00383507247TRLO0.1.1

22/12/2023

09:07:47

1148

150.8

CHIX

00383509008TRLO0.1.1

22/12/2023

09:07:47

84

151

CHIX

00383509009TRLO0.1.1

22/12/2023

09:13:32

990

151.8

CHIX

00383509915TRLO0.1.1

22/12/2023

09:13:32

194

151.8

TRQX

00383509917TRLO0.1.1

22/12/2023

09:13:32

1695

151.8

XLON

00383509916TRLO0.1.1

22/12/2023

09:47:30

57

153.2

BATE

00383514659TRLO0.1.1

22/12/2023

09:49:22

372

152.2

AQXE

00383515070TRLO0.1.1

22/12/2023

09:49:22

865

152.2

BATE

00383515071TRLO0.1.1

22/12/2023

09:49:22

1130

152.2

CHIX

00383515072TRLO0.1.1

22/12/2023

09:49:22

1695

152.2

XLON

00383515073TRLO0.1.1

22/12/2023

09:49:22

194

152.2

TRQX

00383515074TRLO0.1.1

22/12/2023

10:41:15

140

151.4

BATE

00383521458TRLO0.1.1

22/12/2023

10:54:43

48

152.6

AQXE

00383524055TRLO0.1.1

22/12/2023

10:54:43

68

152.6

AQXE

00383524056TRLO0.1.1

22/12/2023

10:55:17

279

152.6

AQXE

00383524175TRLO0.1.1

22/12/2023

11:00:35

565

151.6

BATE

00383525058TRLO0.1.1

22/12/2023

11:00:35

785

151.6

AQXE

00383525057TRLO0.1.1

22/12/2023

11:00:35

1130

151.6

CHIX

00383525059TRLO0.1.1

22/12/2023

11:00:35

2260

151.6

XLON

00383525060TRLO0.1.1

22/12/2023

11:00:35

194

151.6

TRQX

00383525061TRLO0.1.1

22/12/2023

11:04:59

1130

151.8

CHIX

00383525860TRLO0.1.1

22/12/2023

11:08:55

464

151.8

CHIX

00383526673TRLO0.1.1

22/12/2023

11:36:23

869

153.6

XLON

00383530857TRLO0.1.1

22/12/2023

11:36:23

710

153.6

XLON

00383530858TRLO0.1.1

22/12/2023

11:36:26

412

153.6

XLON

00383530877TRLO0.1.1

22/12/2023

11:36:34

482

153.6

XLON

00383530899TRLO0.1.1

22/12/2023

11:36:38

259

153.6

XLON

00383530905TRLO0.1.1

22/12/2023

11:36:42

330

153.6

XLON

00383530912TRLO0.1.1

22/12/2023

11:36:58

71

154.2

CHIX

00383531014TRLO0.1.1

22/12/2023

11:37:31

990

158.6

BATE

00383531075TRLO0.1.1

22/12/2023

11:37:51

440

158.2

CHIX

00383531113TRLO0.1.1

22/12/2023

11:37:51

250

158.2

CHIX

00383531114TRLO0.1.1

22/12/2023

11:37:51

586

158.2

XLON

00383531116TRLO0.1.1

22/12/2023

11:37:51

3173

158.2

XLON

00383531115TRLO0.1.1

22/12/2023

11:37:51

371

158.2

XLON

00383531117TRLO0.1.1

21/12/2023

16:29:51

64

150.6

XLON

00383452416TRLO0.1.1

21/12/2023

16:29:55

153

150.6

TRQX

00383452507TRLO0.1.1

21/12/2023

16:29:55

329

150.6

XLON

00383452508TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFVDFLLFFIV
Date   Source Headline
24th Mar 20217:00 amRNSHolding(s) in Company
18th Mar 20217:00 amRNSDirectorate Change
15th Mar 20217:00 amRNSNotice of Results
3rd Mar 202112:00 pmRNSPRTC Presents at Barclays Healthcare Conference
2nd Mar 20211:01 pmRNSKaruna Prices Approximately $250M Public Offering
25th Feb 20212:00 pmRNSPRTC Publishes Lymphatic Targeting Study for Glyph
25th Feb 20217:00 amRNSKaruna data in New England Journal of Medicine
18th Feb 202112:00 pmRNSPRTC Presents at SVB Leerink Healthcare Conference
10th Feb 20217:05 amRNSVor Closes Over $200M Initial Public Offering
10th Feb 20217:00 amRNSPRTC Receives $118M from Founded Entity Shares
8th Feb 202112:00 pmRNSVedanta Adds Biotech Finance and IR Expert as CFO
5th Feb 202111:46 amRNSPureTech Founded Entity Vor Lists on Nasdaq
5th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20217:00 amRNSPureTech Appoints Bharatt Chowrira to BOD
18th Jan 20217:00 amRNSVor Files IPO Registration Statement on Nasdaq
14th Jan 202112:05 pmRNSVor Announces FDA Acceptance of IND Application
14th Jan 202111:50 amRNSAesthetic Med & Dermatology Veterans Join Follica
12th Jan 202111:50 amRNSVedanta Receives $25M Investment from Pfizer Inc
5th Jan 20217:00 amRNSPRTC Appoints Biotech Analyst & Senior Exec as CFO
4th Jan 20217:00 amRNSTotal Voting Rights
21st Dec 202012:00 pmRNSPureTech to Present at JPM and Other Conferences
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202012:00 pmRNSPRTC Starts LYT-200 Clinical Trial in Solid Tumors
11th Dec 20207:00 amRNSHolding(s) in Company
10th Dec 202012:00 pmRNSLYT-100 Advances to Phase 2a Study in Lymphedema
9th Dec 202012:00 pmRNSFollica Female Hair Loss Academic Study Published
3rd Dec 202012:00 pmRNSPureTech Initiates Ph 2 of LYT-100 in Long COVID
1st Dec 20207:00 amRNSTotal Voting Rights
30th Nov 202012:00 pmRNSPureTech to Host Virtual R&D Day for Investors
27th Nov 20204:41 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
27th Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
27th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Nov 202012:00 pmRNSVedanta Appoints Karuna CFO Troy Ignelzi to BOD
23rd Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th Nov 20207:00 amRNSPRTC LYT-100 Shows PK & Tolerability Ph1 POC
16th Nov 20207:00 amRNSPureTech to Present at Three Investor Conferences
13th Nov 20205:05 pmRNSGuidance for Exchanging Ordinary Shares into ADSs
13th Nov 20205:00 pmRNSDirector/PDMR Shareholding
13th Nov 20201:04 pmRNSGelesis Presents New Data at The Liver Meeting
13th Nov 20207:00 amRNSPureTech to Commence Nasdaq Trading on 16 November
12th Nov 20202:04 pmRNSSonde Respiratory Portal Available to Developers
11th Nov 20201:03 pmRNSVor Licenses Clinical-Stage CD33 CAR-T Therapy
5th Nov 20207:00 amRNSPureTech Presents at Credit Suisse Conference
3rd Nov 20205:10 pmRNSGelesis Presents New Data at ObesityWeek
2nd Nov 20204:35 pmRNSDirector/PDMR Shareholding
28th Oct 20207:00 amRNSPureTech Files Publicly for Nasdaq Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.